<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01750476</url>
  </required_header>
  <id_info>
    <org_study_id>PRO12010187</org_study_id>
    <secondary_id>R01HD072663</secondary_id>
    <nct_id>NCT01750476</nct_id>
  </id_info>
  <brief_title>Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives</brief_title>
  <official_title>Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Cherpes, DVM, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are conducting a research study to understand how cells responsible for
      fighting infection (immune cells) are affected by hormonal contraceptive use. The
      investigators hypothesize that progestin-containing hormonal contraceptives (i.e.,
      Depo-Provera) inhibit host response to infection. To test this hypothesis, the investigators
      will collect blood and genital tract samples from women before and after their initiation of
      a hormonal contraceptive (either birth control pills, Depo-Provera, or Mirena).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI and lab have re-located study to The Ohio State University
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proliferative capacity (i.e., ability to respond to antigen stimulation) of T cells isolated from the cervix of women before and after initiating a hormonal contraceptive</measure>
    <time_frame>Prior to and ~ 1 month (but up to 2 months) after initiation of a hormonal contraceptive</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">7</enrollment>
  <condition>Initiation of Oral Contraception (OC)</condition>
  <condition>Initiation of Depo-Provera (DMPA)</condition>
  <condition>Initiation of Mirena (LNG-IUD)</condition>
  <arm_group>
    <arm_group_label>Depo-Provera</arm_group_label>
    <description>Women who choose to initiate Depo-Provera</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirena</arm_group_label>
    <description>Women who choose to initiate Mirena (intrauterine device)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral contraception</arm_group_label>
    <description>Women who choose to initiate oral contraception</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirena</intervention_name>
    <arm_group_label>Mirena</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral contraception</intervention_name>
    <arm_group_label>Oral contraception</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depo-Provera</intervention_name>
    <arm_group_label>Depo-Provera</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women interested in initiating hormonal contraceptive use
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 15-25 years of age (inclusive)

          2. History of regular menstrual cycle

          3. Not pregnant

          4. No plan to become pregnant in the next 3 months

          5. Interested in beginning use of OC, DMPA, or LNG-IUD

          6. Able to read and provide written informed consent (and consent from a parent/guardian
             if the participant is a minor)

        Exclusion Criteria:

          1. Anticipated move out of area that prevents return for a follow-up visit

          2. Unavailability for follow-up visit

          3. Less than 90 days post-partum or post-abortion

          4. Sexually transmitted infection (STI) diagnosed less than 30 days prior to enrollment

          5. Use of OC, contraceptive ring or patch, single rod implant, LNG-IUD, or
             copper-containing IUD less than 3 months prior to enrollment

          6. DMPA injection less than 6 months prior to enrollment

          7. History of immunosuppressive condition of current use of immunosuppressive medications

          8. History of a cervical malignancy

          9. Detection of cervical anatomic pathologic conditions that preclude cervical biopsy
             procurement

         10. Intolerance or contradiction to use of OC, DMPA, or LNG-IUD
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas L. Cherpes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>assistant professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Adolescent Clinic of Oakland</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vicetti Miguel RD, Hendricks RL, Aguirre AJ, Melan MA, Harvey SA, Terry-Allison T, St Leger AJ, Thomson AW, Cherpes TL. Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection. J Immunol. 2012 Oct 1;189(7):3449-61. Epub 2012 Aug 31.</citation>
    <PMID>22942424</PMID>
  </reference>
  <reference>
    <citation>Vicetti Miguel RD, Maryak SA, Cherpes TL. Brefeldin A, but not monensin, enables flow cytometric detection of interleukin-4 within peripheral T cells responding to ex vivo stimulation with Chlamydia trachomatis. J Immunol Methods. 2012 Oct 31;384(1-2):191-5. doi: 10.1016/j.jim.2012.07.018. Epub 2012 Jul 29.</citation>
    <PMID>22850275</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2012</study_first_submitted>
  <study_first_submitted_qc>December 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <last_update_submitted>January 5, 2014</last_update_submitted>
  <last_update_submitted_qc>January 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Thomas Cherpes, DVM, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>oral contraception</keyword>
  <keyword>Depo-Provera</keyword>
  <keyword>Mirena</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

